ELI LILLY AND COMPANY stock forum
LLY just shared full analysis on LLY Idea:Eli Lilly’s Competitive Edge |…
SPX
LLY folks here if you guys missed ALLO , I have got Veru.. train leaving station
LLY fly baby fly
LLY Lilly Endowment sells $31.18 million in Eli Lilly stock. So, bulls continues next week.LLY Nice 3% short from 875 thanks ! LLY loves to be dumped at 1hr before market close.LLY if you guys missed ALLO, here is another stock I got bags off.. Veru , DYOR, I see minimum 60 - 100%LLY who all followed me buying ALLO. Hope you guys happyLLY Shorting initiated second half of the market hmm.LLY CVS Earning call beat definitely suggest strong demand for drugs, LLY is in one of them, I sense incoming 900 price by this week.LLY Eli Lilly's revenue soared 45% year-over-year to $13.5 billion, surpassing expectations by $100 million. This growth was fueled by strong sales of Mounjaro ($3.5 billion) and Zepbound ($1.9 billion), both aligning with pre-announced figures. Although sales fell short of initial projections in the previous quarter, the company's FY25 revenue guidance of $58-61 billion (+32% Y/Y) reassured investors. Management highlighted a planned 60% increase in GLP-1 supply during the first half of 2025 to meet rising demand, while the removal of Mounjaro and Zepbound from the FDA’s shortage list is expected to limit compounded alternatives and strengthen Lilly’s market dominance. With recent regulatory approvals for Kisunla and Ebglyss, expanded global rollouts for Mounjaro, and ongoing reimbursement negotiations for Zepbound, Lilly continues to reinforce its leadership in the obesity and diabetes space. Management remains optimistic about long-term growth, citing the need for further capacity expansion to keep pace with demand. The next major catalyst will be mid-year Phase 3 trial results for Orforglipron, Lilly’s oral obesity treatment.
SPX 
NDX 
DXY